Global Information
회사소개 | 문의 | 위시리스트

군발성 두통 증후군 : 파이프라인 리뷰

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 01월 상품 코드 465225
페이지 정보 영문 58 Pages
가격
US $ 2,000 ₩ 2,429,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,858,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,287,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


군발성 두통 증후군 : 파이프라인 리뷰 Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2019
발행일 : 2019년 01월 페이지 정보 : 영문 58 Pages

군발성 두통은 두부의 한쪽을 따라 통증이 발생합니다. 눈 주위 및 뒤, 또는 위에 통증이 잘 발생합니다. 증상은 타는 듯한 통증, 지속성 통증, 결막충혈, 콧물, 눈물 분비, 안면 홍조 등입니다. 위험인자에는 연령 및 성별이 있습니다. 치료에는 항염증약(스테로이드) 및 트립탄을 이용합니다.

군발성 두통 증후군 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

군발성 두통 증후군;개요

치료제 개발

  • 파이프라인 제품;개요
  • 기업에서 개발중인 제품
  • 기업에서 개발중인 치료제

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 유형별

치료제 개발에 참여하고 있는 기업

  • Eli Lilly and Company
  • Entheogen Corp
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • TrioxBio Inc

약제 개요

  • BOL-148
  • fremanezumab
  • galcanezumab
  • MTR-108
  • pasireotide
  • zucapsaicin

휴지중인 프로젝트

부록

도표

KSA 17.03.24

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Clexio Biosciences Ltd, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Crossject SA, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Eli Lilly and Co, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Novartis AG, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by TrioxBio Inc, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Dormant Projects, H1 2019

List of Figures

  • Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H1 2019 7
  • Number of Products under Development by Companies, H1 2019 8
  • Number of Products by Targets, H1 2019 13
  • Number of Products by Stage and Targets, H1 2019 13
  • Number of Products by Mechanism of Actions, H1 2019 15
  • Number of Products by Stage and Mechanism of Actions, H1 2019 15
  • Number of Products by Routes of Administration, H1 2019 17
  • Number of Products by Stage and Routes of Administration, H1 2019 17
  • Number of Products by Molecule Types, H1 2019 19
  • Number of Products by Stage and Molecule Types, H1 2019 19

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2019, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.

Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cluster Headache Syndrome (Cluster Headache) - Overview
  • Cluster Headache Syndrome (Cluster Headache) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cluster Headache Syndrome (Cluster Headache) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cluster Headache Syndrome (Cluster Headache) - Companies Involved in Therapeutics Development
    • Clexio Biosciences Ltd
    • Crossject SA
    • Eli Lilly and Co
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • TrioxBio Inc
  • Cluster Headache Syndrome (Cluster Headache) - Drug Profiles
    • CLE-500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fremanezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galcanezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTR-108 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • psilocybin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sumatriptan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zucapsaicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cluster Headache Syndrome (Cluster Headache) - Dormant Projects
  • Cluster Headache Syndrome (Cluster Headache) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache
      • Jun 15, 2018: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
      • May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
      • Apr 17, 2018: Teva to Present New Data on Fremanezumab at 70th Annual Meeting of the American Academy of Neurology
      • Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q